Semaglutide versus resmetirom for noncirrhotic MASH with moderate to advanced fibrosis: a cost-effectiveness analysis
Basile Njei, Yazan A. Al-Ajlouni, Dam Nsoh Tanih, Ulrick Sidney Kanmounye et autres
1 citationCost Effectiveness and Resource Allocation